College of Medicine Welcomes Academic Strength With Incoming Class
The ceremony, on Friday, Aug. 10, featured the coating of each member of the incoming classwhen 160 students will officially began their careers in medicine. And the new class, says
Stern says its normal to have an incoming class with higher averages in one or two academic areas. But he says, the class of 2011 ranks higher across the board.
The incoming students scored particularly well on the Medical College Admissions Test (MCAT), which assesses applicants writing skills and measures abilities in three areasverbal reasoning, physical sciences and biological sciences. UCs class of 2011 scored higher on average in all three areas compared with previous classes. The average total MCAT score for UCs incoming students is 32, compared with 31 for the 2006 entering class and 30 for students admitted in 2005.
The entering class also has an average GPA of 3.7, one-tenth of a point higher than the 2005 entering class.
Its clear that our reputation as a leading academic health center is growing and that our faculty, physicians and investments in facilities are leading that growth, says Stern.
Laura Wexler, MD, associate dean for student affairs and admissions, says academic qualifications are only one piece of the puzzle when assessing medical school candidates.
We arent just looking for students who are academically oriented, says Wexler. We seek students who will become outstanding physicians and community leaders.
The most well-rounded and competitive students have lots of options, so its always reassuring to see so many of them choosing our schoolnot just for our reputation, but for the quality education they know theyll receive.
Fridays ceremony will begin at 1 p.m. at
A reception will follow. For more information, call (513) 558-5577 or e-mail ivadean.lair@uc.edu.
Related Stories
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia
September 1, 2026
The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.
Heavy social media use linked to depression
August 31, 2026
U.S. News and World Report, Yahoo! News, MSN, USA Today and other national media highlight a new study by the University of Cincinnati and Northwestern University that found a correlation between heavy social media use and depression in adults.